Your browser is no longer supported. Please, upgrade your browser.
CPRX Catalyst Pharmaceuticals, Inc. daily Stock Chart
Catalyst Pharmaceuticals, Inc.
Index- P/E12.31 EPS (ttm)0.40 Insider Own6.89% Shs Outstand103.41M Perf Week-1.20%
Market Cap521.20M Forward P/E10.12 EPS next Y0.49 Insider Trans0.00% Shs Float96.29M Perf Month20.98%
Income42.90M PEG- EPS next Q0.09 Inst Own65.20% Short Float12.56% Perf Quarter12.86%
Sales119.00M P/S4.38 EPS this Y190.70% Inst Trans-0.75% Short Ratio6.71 Perf Half Y16.98%
Book/sh0.96 P/B5.17 EPS next Y30.67% ROA42.40% Target Price8.25 Perf Year21.57%
Cash/sh0.97 P/C5.12 EPS next 5Y- ROE52.30% 52W Range2.55 - 7.67 Perf YTD32.27%
Dividend- P/FCF- EPS past 5Y26.50% ROI34.60% 52W High-35.33% Beta1.93
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin85.50% 52W Low94.51% ATR0.24
Employees76 Current Ratio6.60 Sales Q/Q134.70% Oper. Margin36.50% RSI (14)58.56 Volatility4.64% 5.29%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin36.10% Rel Volume0.71 Prev Close4.74
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout0.00% Avg Volume1.80M Price4.96
Recom- SMA205.19% SMA507.90% SMA20011.21% Volume1,274,168 Change4.64%
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-07-18Resumed Piper Jaffray Overweight
Oct-05-16Upgrade Piper Jaffray Neutral → Overweight
Apr-26-16Downgrade Piper Jaffray Overweight → Neutral $6 → $1
Sep-30-14Reiterated ROTH Capital Buy $5 → $6
Sep-16-14Reiterated ROTH Capital Buy $3.50 → $5
Sep-15-14Reiterated H.C. Wainwright Buy $5 → $13
Oct-21-13Reiterated Aegis Capital Buy $4 → $5.50
Sep-24-13Initiated Maxim Group Buy $4
Sep-06-13Reiterated Aegis Capital Buy $3.50 → $4
Apr-18-13Initiated Aegis Capital Buy $2.50
Aug-27-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $3.70
Oct-01-09Upgrade Merriman Sell → Neutral
May-29-09Downgrade Merriman Curhan Ford Buy → Sell
May-29-09Downgrade Hapoalim Neutral → Underperform
Dec-15-08Initiated Merriman Curhan Ford Buy
Nov-28-07Initiated Rodman & Renshaw Mkt Outperform $9
Jan-31-07Initiated Stifel Nicolaus Buy $9
Jan-05-07Initiated First Albany Buy $10
Jul-14-20 12:55PM  
Jul-10-20 01:48PM  
Jul-09-20 03:03PM  
Jun-23-20 08:03AM  
Jun-22-20 10:49AM  
Jun-18-20 09:12PM  
Jun-10-20 11:30AM  
Jun-01-20 08:03AM  
May-17-20 08:31AM  
May-14-20 08:18AM  
May-11-20 07:25PM  
May-04-20 08:03AM  
Apr-29-20 10:02AM  
Apr-15-20 11:30AM  
Apr-08-20 06:00AM  
Apr-06-20 09:04AM  
Mar-17-20 06:30AM  
Mar-16-20 05:26PM  
Mar-10-20 08:03AM  
Mar-09-20 12:30PM  
Feb-27-20 08:03AM  
Feb-26-20 08:03AM  
Feb-24-20 09:42AM  
Feb-06-20 08:03AM  
Feb-04-20 08:02AM  
Jan-15-20 08:58AM  
Jan-07-20 09:17AM  
Jan-06-20 08:03AM  
Jan-03-20 05:15PM  
Dec-24-19 06:33AM  
Dec-13-19 02:45PM  
Dec-12-19 11:30AM  
Nov-29-19 09:39AM  
Nov-26-19 08:03AM  
Nov-16-19 08:15AM  
Nov-13-19 02:05PM  
Nov-12-19 06:26PM  
Nov-11-19 05:21PM  
Nov-08-19 10:33AM  
Nov-07-19 06:15PM  
Nov-01-19 12:32PM  
Oct-31-19 10:45AM  
Oct-30-19 06:03AM  
Oct-29-19 03:16PM  
Oct-25-19 08:38AM  
Oct-19-19 09:56PM  
Oct-01-19 03:06PM  
Sep-25-19 08:02AM  
Sep-23-19 02:55PM  
Sep-19-19 10:37AM  
Sep-18-19 09:31AM  
Sep-13-19 10:00AM  
Sep-11-19 04:19PM  
Sep-10-19 03:18PM  
Sep-06-19 09:48PM  
Aug-29-19 08:44AM  
Aug-28-19 08:03AM  
Aug-27-19 02:39PM  
Aug-19-19 12:00PM  
Aug-16-19 07:54AM  
Aug-13-19 11:42AM  
Aug-08-19 03:06PM  
Aug-07-19 06:55PM  
Aug-01-19 04:09PM  
Jul-31-19 09:12AM  
Jul-08-19 08:58AM  
Jul-05-19 12:04PM  
Jul-02-19 12:14PM  
Jun-27-19 12:46PM  
Jun-26-19 02:07PM  
Jun-25-19 08:37AM  
Jun-13-19 05:46PM  
Jun-12-19 09:46AM  
Jun-04-19 08:03AM  
May-30-19 08:03AM  
May-29-19 12:08AM  
May-28-19 02:33PM  
May-22-19 03:47PM  
May-18-19 07:15AM  
May-16-19 11:00AM  
May-14-19 02:36PM  
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
INGENITO GARYChief Medical OfficerDec 05Sale4.82150,000723,1500Dec 06 04:52 PM
INGENITO GARYChief Medical OfficerDec 04Option Exercise2.53150,000379,500150,000Dec 06 04:52 PM
INGENITO GARYChief Medical OfficerNov 27Option Exercise1.13100,000113,000100,000Nov 27 05:02 PM
INGENITO GARYChief Medical OfficerNov 27Sale4.66100,000466,0000Nov 27 05:02 PM
INGENITO GARYChief Medical OfficerNov 21Sale4.50100,000449,8000Nov 22 05:06 PM
INGENITO GARYChief Medical OfficerNov 20Option Exercise0.79100,00079,000100,000Nov 22 05:06 PM
O'Keeffe Charles BDirectorOct 11Buy4.7010,00046,950553,376Oct 11 02:58 PM
MCENANY PATRICK JPresident and CEOOct 03Buy4.8910,00048,9004,772,693Oct 03 03:10 PM